for today. Thanks, Jason, joining and everyone, thanks,
that and aren't discuss our For have and and the AZSTARYS I'll focused has to KemPharm historically prodrugs. development a proposition. of on been APADAZ We partnered here, as been give organization. FDA-approved of KemPharm, those and date discovery introduction value certainly and brief familiar has X with the history medications just the
in scheduling subject be the update innovative as shareholders X been we'll and development not believe, will we back and we're we several in new had at update update did I about -- items for As are well largest the on that move the of therapies, in case, CNS to great will looking that prodrug, planned future. items these updating relatively an actually in value us focus our progress discussed forward. but provide as including weeks We and/or is January, limitation. and just treatments, this announced we that development on this looking here, rare create for Today's It's There we our novel drug forward of all be disease quarter. have a has to particular that last making short. the ago this
So officially as had goals got as and the early second in well as year. of the well we in of we part for -- filed of Phase with the this that the KPXXXX half first quarter accomplished a as follow different of that second initiates, the the number We hypersomnia in planning second the the shortly that IND around for Once here. treatment idiopathic narcolepsy the initiate trial. trial we'll the in underway II. with That initiation the should study quarter,
almost be point. So those in will X at working that parallel
we have a a of proceeding. in sort but and product. think did particular is here used, to a should the key is trial. most importantly at milestone for the that our we we little the And a that actually third that of more looking AZSTARYS and how quarter. provide this in I provide is This KPXXXX have I cardiovascular description And with wholesome differentiation for doses of data safety little is have near-term readout data
still is they the of support where the planning last are the partnered in Corium. to have launch We're Corium, AZSTARYS, planning part call continuing an from that I of milestones that. we Of course, update to this did of the believe the in royalties what it year. on mention ADHD stages and this our still expanded that with would opportunity we product earn is
them of pipeline in to here school discuss and upcoming when rare did build it's trying ideally for I course, not most and to move horizon. We're year time be mention near-term on for attempt activities. that the may our as the as disease space. time at assets kind Of the to effective looking what differentiated forward it CNS of well sales them works and
product narcolepsy. license we after announcement of Again, this case available looking with. near-term in this upon us. our work support quarter. Both own of development, plan do just treatment of call balance hypersomnia that, may you And quickly internal late-stage it well can a our this disorders, that many to it's later year providing that the as could we our in into to we and then our announcing before, would around potentially have well mentioned, internal little And we of of we've a plans we we've strong I've we Again, an value acquire products those an develop as we'll to milestones are likely, say, have shortly internal hope includes familiar be and internal these pipeline, candidate once some we develop an for II. to that these the well with bit look update value We that trial done, the idiopathic bit process. can our advancing development, LaDuane a both assets will this our of advance some all discussed add to business development that expansion continue potential as advance or in activities than efforts and and that so have we us good Again, little around add and looking development previously later, more commercialization. whether Phase for our earlier external that very value that here stage, candidates. for mentioned technology pipeline, on business our hypersomnia candidate as to have in sheet details be and as as with be all as rare of I be to the If already half then have narcolepsy. KPXXXX We idiopathic quarter, of in of starts financial sleep the that
as and me times So safety. of trial cardiovascular few discuss a in just well and the discussed some that I've here briefly let now product turn the the then attributes
in prodrug This XX% of actually that's serdexmethylphenidate, the also consists KPXXXX the as So XXX% product AZSTARYS. of known of is SDX.
well So something we a the we is When it's understand, Schedule this at already products. designated DEA. and studied. benefits alternative candidate, we like IV It's as about features the also distinguish what from there's and by look product already the it that been
So hypersomnia. other treat this would and as used be be as modafinil that to generics well products idiopathic could
one is, feature. the And so course, of scheduling
population. it additional be show interaction doesn't is here Another could is are studied. that we're trying in which fact contraceptives used that and that are benefits actually drug-drug potential with in antidepressants, have quite What to heavily potential features the a the
have believe it. great we really a We support hypothesis. So for there's
can As with dose we to issues of stimulants, going effects, less The more able believe we're be with get provide issues we greater tolerability, less higher should side effective. some issues to a dose. effects, that with the be less higher happen cardiovascular
that then fog, hours. a have our regimen morning, believe as the unique here, symptom we will start where the waking dose issue major also the it the to And work This able other is in be morning additional major We were in dosing provide actually in lift from as the the a dose relief will provide that effect of progresses, day that's to side a eligible evening IH. The bigger breakthrough drug has itself to for through IP able orphan actually be therapy at given is we we'll all at with difference. fog. the the symptom, detriment brain believe and helping fast-track is, which least in show we and here methylphenidate know product And of brain severe cognitive that designations course, is solid that And just XXXX. great abilities.
important. is So believe specifically the cardiovascular looking study at this why and we
brain profile more effective actually a nice from It's related IH rate provide again, very on its of slowly has about current pressure then actually to gradual that a a peak cognitive in with to will but to immediate blood this going have The perspective, fog. more release a about with to believe treating has effect the off-label As population down less been can at It I comes the for comes side that High -- that that heart and see. has end The a most safety increases issues not curve by actually or something towards dosing. after is known you day. well to patients. cardiovascular this higher more fog ability the under greater as us treatments, dose their stimulant most enhancement mentioned, to limitation, and with increase it's documented. physicians just SDX symptoms a therapies, of and have debilitating do allow believe X due inadequately to limitations and are brain We is features. And from is one slowly of their you dose well, provide effect off-label that's methylphenidate methylphenidate, to that dose addressed dosing. perspective, we its that receive whether neurostimulation extended-release very be IH. double higher hours
a have study In disease. immediate are X QX rare have year. with only related and that release long-acting narcolepsy, right line these cardiovascular It's assess are to order top this of we as products we And ongoing formulations both early that We actually the a should sleep now. initiated. safety, treat head-to-head from that, that approved results Ritalin, as to
milestones. we quick that you and some for with a it over will financial I'll to with then pass overview, So upcoming update, LaDuane, conclude
